EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

European biotechnology - scourge or saviour of the basic scientist?


Trends in Biotechnology 12(7): 253-254
European biotechnology - scourge or saviour of the basic scientist?
This article explores the dilemma facing governments and the scientific community on the role of science, particularly biotechnology, and how its public funding may be justified. It is argued that, despite efforts from the European Union, academic research in Europe is still being not successfully converted into industrial applications. Both the number of European biotechnology companies and patents issued are considerably smaller than those in the USA. Some important lessons that can be learnt from the USA experience are summarised. Changes are suggested to promote biotechnology transfer in Europe, including: the redefinition of the European Commission role on training and research project management, encouragement of PhD training at the academic-industry interface, professionalization of industrial liaison in academic institutions, maintenance of a smaller core of scientists engaged in fundamental research, increase in the number of publicly funded scientists engaged in applied science and more participation of industrial scientists in funding agencies.

Accession: 002373924

PMID: 7765072

DOI: 10.1016/0167-7799(94)90134-1

Download PDF Full Text: European biotechnology - scourge or saviour of the basic scientist?



Related references

European biotechnology--scourge or saviour of the basic scientist?. Trends in Biotechnology 12(7): 253-254, 1994

European biotechnology-scourge or savior of the basic scientist?. Trends in Biotechnology 12(7): 253-254, 1994

European biotechnology today The impact of basic sciences on diagnosis and therapy First Conference on European Biotechnology Today. Malavasi, F , Cortese, R , Albertini, A European biotechnology today: The impact of basic sciences on diagnosis and therapy : XX+284P, 1992

Biotechnology--savior or scourge?. Activities report of the R and D Associates3(1-2): 298-304, 2000

Safe biotechnology 10: DNA content of biotechnological process waste. The Safety in Biotechnology Working Party of the European Federation of Biotechnology. Trends in Biotechnology 18(4): 141-146, 2000

Safe biotechnology. 7. Classification of microorganisms on the basis of hazard. Working Party "Safety in Biotechnology" of the European Federation Biotechnology. Applied Microbiology and Biotechnology 45(6): 723-729, 1996

Safe biotechnology. 8. Transport of infectious and biological materials. Working Party "Safety in Biotechnology" of the European Federation of Biotechnology. Applied Microbiology and Biotechnology 48(2): 135-140, 1997

Safe biotechnology 9: values in risk assessment for the environmental application of microorganisms. The Safety in Biotechnology Working Party of the European Federation of Biotechnology. Trends in Biotechnology 17(8): 307-311, 1999

Interface between basic medical sciences and their clinical branches Views of a basic scientist. 1964

Cambridge studies in biotechnology 6 patents a basic guide to patenting in biotechnology. Crespi, R S Cambridge Studies in Biotechnology, 6 Patents: A Basic Guide to Patenting in Biotechnology Vii+191p Cambridge University Press: New York, New York, Usa; Cambridge, England, Uk Illus Vii+191p, 1988